Murad correction
This article was originally published in The Rose Sheet
Executive Summary
Murad Acne Complex direct advertising claims, including "Get Clear. Stay Clear" and "Acne Complex has been proven in clinical trials to have an unheard of 90% success rate," were found by the Council of Better Business Bureaus' Electronic Retailing Self-Regulation Program to be substantiated for treatment of the visible factors of breakouts, and would not need to be modified as reported in "The Rose Sheet" Feb. 21, 2005, p. 9. However, use of the two claims together should only refer to acne breakouts to prevent the consumer perception the product addresses non-acne conditions, according to ERSP. The watchdog group also concluded that implied claim that Acne Complex treats all the reasons skin breaks out, which include internal factors, were unsubstantiated. Murad disagreed with the assessment and notes the company did not need to submit supporting data for a claim it believed was not made...
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.